Trials / Unknown
UnknownNCT05352347
Phase 2b/3 Trial of NuSepin® in COVID-19 Pneumonia Patients
A Randomized, Double-blinded, Placebo-controlled, Parallel-treatment Group, Adaptive Design, Multi-center, Phase 2b/3 Trial to Evaluate Efficacy and Safety of NuSepin® Intravenous Infusion in COVID-19 Pneumonia Patients
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 1,134 (estimated)
- Sponsor
- Shaperon · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
A Randomized, Double-blinded, Placebo-controlled, Parallel-treatment Group, Adaptive Design, Multi-center, Phase 2b/3 Trial to Evaluate Efficacy and Safety of NuSepin® Intravenous Infusion in COVID-19 Pneumonia Patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NuSepin® 0.2 mg/kg | NuSepin® 0.2 mg/kg in 100mL NS bid |
| DRUG | NuSepin® 0.4 mg/kg | NuSepin® 0.4 mg/kg in 100mL NS bid |
| DRUG | Placebo | Normal saline (NS) 100mL bid |
Timeline
- Start date
- 2022-04-12
- Primary completion
- 2024-11-30
- Completion
- 2024-12-31
- First posted
- 2022-04-28
- Last updated
- 2023-03-21
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05352347. Inclusion in this directory is not an endorsement.